FEBBRAIO 2025
UC
Dott. Marco Daperno
A.O Ordine Mauriziano, Torino, Italia
- Mirikizumab demonstrates rapid improvements in bowel urgency severity, bowel urgency frequency, and stool deferral time in patients with moderately-to-severely active Ulcerative Colitis: 12-week interim results from the phase 3b LUCENT-URGE trial
- Efficacy and safety of the mirikizumab extended induction cohort at 152 weeks of continuous treatment for moderately to severely active Ulcerative Colitis: Results from the LUCENT-3 open-label extension study
Prof.ssa Fabiana Castiglione
Università degli Studi di Napoli Federico II, Napoli, Italia
- Proactive fecal calprotectin testing in ulcerative colitis: Initial results of the PROMOTE UC study
- Real-world data of Mirikizumab in the induction and maintenance therapy for ulcerative colitis
Prof. Paolo Gionchetti
Università di Bologna, Policlinico Sant'Orsola, Bologna, Italia
- Early symptom improvements predict later clinical response and remission at week 12 for patients with ulcerative colitis treated with mirikizumab in the LUCENT-1 study
- Histologic remission predicts relapse in patients with Ulcerative Colitis
Prof. Sandro Ardizzone
Humanitas San Pio X, Milano, Italia
- Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
Prof.ssa Sara Onali
Università degli Studi di Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italia
- Sequencing Therapy for Optimal Response in Mirikizumab (STORM) Study
- Course of patients with Ulcerative colitis who have achieved disease clearance from the moment of diagnosis
Prof. Edoardo Vincenzo Savarino
Università di Padova, Padova, Italia
- The Burden of Urgency in Ulcerative Colitis: Impact of Disease Duration and Activity
- Evaluating Tryptophan as a Biomarker for Treatment Success in Ulcerative Colitis Patients Undergoing Mirikizumab Therapy
Prof. Massimo Claudio Fantini
Segretario generale IG-IBD, Università di Cagliari, AOU Cagliari, Italia
- Congresso ECCO 2025: cosa ci portiamo a casa?
Dott.ssa Federica Furfaro
IRCCS Ospedale San Raffaele, Università Vita- Salute San Raffaele, Milano, Italia
- Pharmacokinetic comparability and safety between original and citrate-free mirikizumab formulations for subcutaneous injections: Results from three clinical trials in healthy participants
Prof. Flavio Caprioli
Università degli Studi di Milano, Fondazione IRCCS Cà Granda, Ospedale Policlinico, Milano, Italia
- A Comparison of the Milan Ultrasound Criteria with the Ulcerative Colitis Intestinal Ultrasound Index to Assess Disease Activity in Patients with Ulcerative Colitis
- Correlation between endoscopic scores and Nancy histological Index in ulcerative colitis: A real-world, single-center prospective study
Prof. Franco Scaldaferri
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma
- Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study
- La mission dell'ECCO per il clinico italiano
Dott.ssa Olga Maria Nardone
Università degli Studi di Napoli Federico II, Napoli, Italia
- Novel AI-Driven Detection, Localisation and Quantification of Neutrophils for Prediction of Early Response to Therapy in a Phase 2 Ulcerative Colitis Clinical Trial
- Impact of pharmacological therapies for moderate to severe Ulcerative Colitis on health-related quality of life: a systematic review and network meta-analysis